Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Prostate Specific Antigen Dynamics and Prostate Cancer Risk: A Population-Based Study
EF 2018-19
Résumé
Prostate cancer will affect one in seven Canadian men. Prostate cancer can be detected early using a screening blood test, called prostate specific antigen (PSA). While PSA is almost always increased in men with prostate cancer, other conditions can also increase the PSA. This can lead to unnecessary biopsies and has caused debate about the usefulness of PSA as a screening tool. Newer tools, such as magnetic resonance imaging (MRI), are beginning to be used with the PSA blood test to determine when the risk of cancer is highest and when a prostate biopsy is needed. However, the benefits of these tests are still undetermined, and their high cost limits their use. Given the debate around PSA screening, it is important to find a new way to interpret the PSA that will better identify men at the highest risk of having prostate cancer.
The Ontario Laboratory Information System contains more than one million PSA results for tens of thousands of men in Ontario. This system has been recently linked to large cancer-specific population datasets. This linkage provides the unique opportunity to study PSA change and prostate cancer risk among men in a real-world setting. I will develop a model to determine when to complete a prostate biopsy based on patient characteristics, PSA level, number of prior PSA tests and PSA change over time. This can be achieved at no additional cost to the health care system and at no additional cost or inconvenience to the patient. This project will result in better identification of high-risk patients and has the potential to transform prostate cancer screening.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
406416
Name
Hird Amanda E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Prostate Specific Antigen Dynamics and Prostate Cancer Risk: A Population-Based Study
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Nomogram; Population Screening; Prediction Tool; Prostate Cancer; Prostate Specific Antigen
Abstract
Prostate cancer will affect one in seven Canadian men. Prostate cancer can be detected early using a screening blood test, called prostate specific antigen (PSA). While PSA is almost always increased in men with prostate cancer, other conditions can also increase the PSA. This can lead to unnecessary biopsies and has caused debate about the usefulness of PSA as a screening tool. Newer tools, such as magnetic resonance imaging (MRI), are beginning to be used with the PSA blood test to determine when the risk of cancer is highest and when a prostate biopsy is needed. However, the benefits of these tests are still undetermined, and their high cost limits their use. Given the debate around PSA screening, it is important to find a new way to interpret the PSA that will better identify men at the highest risk of having prostate cancer.
The Ontario Laboratory Information System contains more than one million PSA results for tens of thousands of men in Ontario. This system has been recently linked to large cancer-specific population datasets. This linkage provides the unique opportunity to study PSA change and prostate cancer risk among men in a real-world setting. I will develop a model to determine when to complete a prostate biopsy based on patient characteristics, PSA level, number of prior PSA tests and PSA change over time. This can be achieved at no additional cost to the health care system and at no additional cost or inconvenience to the patient. This project will result in better identification of high-risk patients and has the potential to transform prostate cancer screening.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hird, Amanda E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~